PMID

Data

Article Title

Organization

DNA repair and redox activities and inhibitors of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1): a comparative analysis and their scope and limitations toward anticancer drug development.

Central University of Punjab

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.

University of Manchester

Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.

National Center For Advancing Translational Sciences

Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/ref-1).

Purdue University

Discovery of Macrocyclic Inhibitors of Apurinic/Apyrimidinic Endonuclease 1.

Boston University

Inhibitors of nuclease and redox activity of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1).

Russian Academy of Sciences

New insights into homopiperazine-based 5-HT1A/5-HT7R ligands: synthesis and biological evaluation.

University of Orleans

Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, U-97018.

Upjohn Pharmaceuticals

Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity.

Eli Lilly

Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.

Cytopia Research